ESR1 and ovarian carcinoma: On one hand, it is extensively studied and reported that estrogen activates ERα signaling, maintaining epithelial phenotype and suppressing EMT (as reviewed [53]), but on the other hand, estrogen has been found to activate EMT in ER-positive breast and ovarian cancer cells, promoting their stemness and invasiveness [5–7, 54].